Figure 1.
Genomics and outcome of infant patients with MLL-G BCP-ALL. Schematic representation of NUTM1 (A) and PAX5 (B) fusion genes identified in infant patients with MLL-G B-ALL compared with the respective wild-type genes. For each gene, exons and relevant protein domains are indicated at the bottom and top, respectively. Arrows indicate the fusion breakpoints. (C) EFS according to the class of fusion transcript detected in 30 infant patients with MLL-G BCP-ALL. The negative (NEG; no fusion gene detected) curve does not depict 1 relapse (testis) that occurred at 3.1 years. Table reports the details of patients and events. ^Relapses occurred in: TCF3 class (n = 1; died after relapse), ABL class (n = 1), and CRLF2 class (n = 1). BRD, bromodomain; CUT, CUT DNA binding motif; DBD, DNA binding domain; DNA-J, DNA-J peptide binding; FHD, fibrosin homology domain; GDH, glycerate dehydrogenase catalytic domain; HD, homeodomain; ID, inhibitory domain; NAD(P), NAD(P) binding domain; NUT, NUT domain; NUTM1, NUTM1 class fusions; other, other fusions; PAX5, PAX5 fusions; OP, octapepdtie domain; SAP, SAP motif; TAD, transactivation domain; ZF, zinc finger.

Genomics and outcome of infant patients with MLL-G BCP-ALL. Schematic representation of NUTM1 (A) and PAX5 (B) fusion genes identified in infant patients with MLL-G B-ALL compared with the respective wild-type genes. For each gene, exons and relevant protein domains are indicated at the bottom and top, respectively. Arrows indicate the fusion breakpoints. (C) EFS according to the class of fusion transcript detected in 30 infant patients with MLL-G BCP-ALL. The negative (NEG; no fusion gene detected) curve does not depict 1 relapse (testis) that occurred at 3.1 years. Table reports the details of patients and events. ^Relapses occurred in: TCF3 class (n = 1; died after relapse), ABL class (n = 1), and CRLF2 class (n = 1). BRD, bromodomain; CUT, CUT DNA binding motif; DBD, DNA binding domain; DNA-J, DNA-J peptide binding; FHD, fibrosin homology domain; GDH, glycerate dehydrogenase catalytic domain; HD, homeodomain; ID, inhibitory domain; NAD(P), NAD(P) binding domain; NUT, NUT domain; NUTM1, NUTM1 class fusions; other, other fusions; PAX5, PAX5 fusions; OP, octapepdtie domain; SAP, SAP motif; TAD, transactivation domain; ZF, zinc finger.

Close Modal

or Create an Account

Close Modal
Close Modal